PH12020500532A1 - Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin - Google Patents
Combined pharmaceutical formulation comprising dapagliflozin l-proline and metforminInfo
- Publication number
- PH12020500532A1 PH12020500532A1 PH12020500532A PH12020500532A PH12020500532A1 PH 12020500532 A1 PH12020500532 A1 PH 12020500532A1 PH 12020500532 A PH12020500532 A PH 12020500532A PH 12020500532 A PH12020500532 A PH 12020500532A PH 12020500532 A1 PH12020500532 A1 PH 12020500532A1
- Authority
- PH
- Philippines
- Prior art keywords
- dapagliflozin
- metformin
- proline
- pharmaceutical formulation
- combined pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
Abstract
The present invention relates to a combined formulation comprising dapagliflozin L-proline and metformin both. A combined formulation according to the present invention is advantageous for long-term medication because the formulation exhibits not only improved storage stability and property stability and an excellent dissolution rate, but also is highly convenient for dosage. In addition, the combined formulation can be useful for prevention or treatment of diabetes, diabetes-related disease, or diabetic complications.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170126878 | 2017-09-29 | ||
KR1020180079614A KR102369679B1 (en) | 2017-09-29 | 2018-07-09 | Pharmaceutical combination comprising DAPAGLIFLOZIN L-PROLINE and METFORMIN |
PCT/KR2018/011004 WO2019066359A2 (en) | 2017-09-29 | 2018-09-18 | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12020500532A1 true PH12020500532A1 (en) | 2021-03-15 |
Family
ID=66164346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12020500532A PH12020500532A1 (en) | 2017-09-29 | 2020-03-13 | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102369679B1 (en) |
BR (1) | BR112020006395A2 (en) |
PH (1) | PH12020500532A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210121599A (en) * | 2020-03-30 | 2021-10-08 | 한미약품 주식회사 | A composite tablet containing sitagliptin, dapagliflozin, metformin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
RU2712757C3 (en) * | 2009-11-13 | 2021-06-09 | Астразенека Аб | TWO-LAYER TABLET COMPOSITION |
EP2498759B1 (en) * | 2009-11-13 | 2018-08-01 | AstraZeneca AB | Immediate release tablet formulations |
US9555001B2 (en) * | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
TR201202948A2 (en) * | 2012-03-15 | 2012-07-23 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Tablet formulation comprising dapaglyphlosin and prolonged release metaphormin. |
KR101750690B1 (en) * | 2015-10-28 | 2017-06-27 | 주식회사 종근당 | Pharmaceutical composition comprising metformin and lobeglitazone |
CN106924208A (en) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof |
-
2018
- 2018-07-09 KR KR1020180079614A patent/KR102369679B1/en active IP Right Grant
- 2018-09-18 BR BR112020006395-9A patent/BR112020006395A2/en not_active IP Right Cessation
-
2020
- 2020-03-13 PH PH12020500532A patent/PH12020500532A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102369679B1 (en) | 2022-03-04 |
BR112020006395A2 (en) | 2020-09-24 |
KR20190038283A (en) | 2019-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279040A (en) | Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof | |
PH12017501222A1 (en) | Glucagon derivatives with improved stability | |
WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
EA201201617A1 (en) | APPLICATION OF METMORPHINE IN COMBINATION WITH GLUCOKINASE ACTIVATOR AND COMPOSITIONS CONTAINING METMORPHIN AND GLUCOKINASE ACTIVATOR | |
WO2015128403A3 (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue | |
MX336657B (en) | Prevention of hypoglycaemia in diabetes mellitus type 2 patients. | |
PH12019502655A1 (en) | Acylated insulin compound | |
MX2018002223A (en) | Novel insulin derivatives and the medical uses hereof. | |
PH12019501363A1 (en) | Insulin containing pharmaceutical compositions | |
JP2017502074A5 (en) | ||
JOP20210201A1 (en) | Blood glucose lowering compound | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
WO2018097570A3 (en) | Pharmaceutical formulation comprising dapagliflozin l-proline | |
PH12020500532A1 (en) | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin | |
PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
MX2020002312A (en) | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. | |
PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
MX2018011293A (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof. | |
WO2016126026A3 (en) | Composition for treating diabetes and use thereof | |
PL414785A1 (en) | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance | |
WO2014195900A3 (en) | Oral pharmaceutical compositions for use in dyslipidemias | |
EA201991190A1 (en) | PHARMACEUTICAL COMPLEX PRODUCT CONTAINING AMLODIPINE, LOZARTAN AND ROSUVASTATIN | |
NZ724595A (en) | Glucokinase activator compositions for the treatment of diabetes | |
MDS20160124U2 (en) | Method for prophylaxis of prolonged lymphorrhagia in the radical treatment of breast cancer in patients with type 2 diabetes | |
MD4537C1 (en) | Injectable supersaturated acetaminophen solution for spinal administration |